Effect of raloxifene and its interaction with human PTH on bone formation

Journal of Endocrinological Investigation

Volumn 27, Issue 5, 2004, Pages 416-423

  Lin, Y ^a   Liu, L J F ^a   Murray, T ^a   Sodek, J ^b   Rao, Leticia ^a  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Alkaline phosphatase; Bone formation; hPTH (1 34); Raloxifene; SaOS 2 cells

Indexed keywords

6 HYDROXY 2 (4 HYDROXYPHENYL) 3 [4 [2 (1 PYRROLIDINYL)ETHOXY]BENZOYL]BENZO[B]THIOPHENE; ALKALINE PHOSPHATASE; BISINDOLYLMALEIMIDE; CYCLIC AMP DEPENDENT PROTEIN KINASE INHIBITOR; ESTROGEN; MESSENGER RNA; PARATHYROID HORMONE[1-34]; PROTEIN KINASE C INHIBITOR; RALOXIFENE;

ARTICLE; CANCER CELL CULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; ENZYME INHIBITION; GENE EXPRESSION; HUMAN; HUMAN CELL; ONCOGENE C FOS; OSSIFICATION; OSTEOBLAST; OSTEOSARCOMA CELL;

EID: 3242685132     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03345284     Document Type: Article

References (30)

1. Barrett-Connor E. Raloxifene: risks and benefits. Ann N Y Acad Sci 2001, 949: 295-303.
2. Cauley JA, Norton L, Lippman ME, et al. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat 2001, 65: 125-34.
3. Frolik CA, Bryant HU, Black EC, Magee DE, Chandrasekhar S. Time-dependent changes in biochemical bone markers and serum cholesterol in ovariectomized rats: effects of raloxifene HCI, tamoxifen, estrogen, and alendronate. Bone 1996, 18: 621-7.
4. Qu Q, Harkonen PL, Vaananen HK. Comparative effects of estrogen and antiestrogens on differentiation of osteoblasts in mouse bone marrow culture. J Cell Biochem 1999, 73: 500-7.
5. Neer RM, Arnaud CD, Zanchetta RJ, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. New Engl J Med 2001, 344: 1434-41.
6. Rao LG, Wylie JN, Sutherland MS, Murray TM. 17 beta-estra diol and parathyroid hormone potentiate each other's stimulatory effects on alkaline phosphatase activity in SaOS-2 cells in a differentiation-dependent manner. Endocrinology 1994, 134: 614-20.
7. 3 on osteoblastic function in human osteosarcoma SaOS-2 cells - differentiation stage dependence and modulation by 17-β estradiol. Bone 1996, 19: 621-7.
8. 3 in normal human osteoblastic cells and human osteosarcoma SaOS-2 cells are modulated by 17-β estradiol and dependent on stage of differentiation. Biol Pharm Bull 2001, 24: 242-8.
9. Rao LG, Liu LJ-F, Murray TM, McDermott E. 17β-estradiol stimulates bone nodule formation when added intermittently to SaOS-2 cells. Drug Metab Drug Interact 2001, 18: 149-58.
10. Sato M, Zeng GQ, Rowley E, Turner CH. LY353381.HCI: An improved benzothiophene analog with bone efficacy complementary to parathyroid hormone-(1-34). Endocrinology. 1998, 139: 4642-51.
11. Lowry OH. Micromethods for the assay of enzymes. II. Specific procedures. Alkaline phosphatase. Methods Enzymol. 1955, 4: 371-2.
12. Rao LG, Liu LJ-F, Murray TM. Raloxifene stimulates mineralized bone nodule formation when added intermittently to cultures of SaOS-2 cells and ostgeogenic stem cells from normal human bone marrow preparations (hBMOSC). J Bone Miner Res 2001, 16 (suppl 1): S492 (abstract).
13. El-Tanani MKK, Green CD. Two separate mechanisms for ligand-independent activation of the estrogen receptor. Mol Endocrinol 1997, 11: 928-37.
14. Migliaccio S, Wetsel WC, Fox WM, Washburn TF, Korach KS. Endogenous protein kinase-C activation in osteoblast-like cells modulates responsiveness to estrogen and estrogen receptor levels. Mol Endocrinol. 1993, 7: 1133-43.
15. Partridge NC, Opie AL, Opie RT, Martin TJ. Inhibitory effects of parathyroid hormone on growth of osteogenic sarcoma cells. Calcif Tissue Int 1985, 37: 519-25.
16. Kano J, Sugimoto T, Fukase M, Chihara K. Cross talk of dual-signal transduction systems in the regulation of DNA synthesis by parathyroid hormone in osteoblastic osteosarcoma cells. J Bone Miner Res 1993, 8: 323-39.
17. Ishizuya T, Yokose S, Hori M, et al. Parathyroid hormone exerts disparate effects on osteoblast differentiation depending on exposure time in rat osteoblastic cells. J Clin Invest 1997, 99: 2961-70.
18. Kanatani M, Sugimoto T, Takahashi Y, Kaji H, Kitazawa R, Chihara K. Estrogen via the estrogen receptor blocks cAMP-mediated parathyroid hormone (PTH)-stimulated osteoclast formation. J Bone Miner Res 1998, 13: 854-62.
19. Hodsman AB, Drost D, Fraher LJ, et al. The addition of a raloxifene analog (LY117018) allows for reduced PTH (1-34) dosing during reversal of osteopenia in ovariectomized rats. J Bone Miner Res 1996, 14: 675-9.
20. Majeska RJ, Rodan, GA. Alkaline phosphatase inhibition by parathyroid hormone and isoproterenol in a clonal rat osteosarcoma cell line. Possible mediation by cyclic AMP. Calcif Tissue Int 1982, 34: 59-66.
21. Nakatani Y, Tsunoi M, Hakeda Y, Kurihara N, Fujita K, Kumegawa M. Effects of parathyroid hormone on cAMP production and alkaline phosphatase activity in osteoblastic clone MC3T3-E1 cells. Biochem Biophys Res Commun 1984, 123: 894-8.
22. Isogai Y, Akatsu T, Ishizuya T, et al. Parathyroid hormone regulates osteoblast differentiation positively or negatively depending on the differentiation stages. J Bone Miner Res 1996, 11: 1384-93.
23. Terakado A, Tagawa M, Goto S, Yamazaki M, Moriya H, Fujimura S. Elevation of alkaline phosphatase activity induced by parathyroid hormone in osteoblastic cells from the spinal hyperostotic mouse. Calcif Tissue Int 1995, 56: 135-9.
24. Azarani A, Orlowski J, Goltzman D. Parathyroid hormone and parathyroid hormone-related peptide activate the Na+/H+ exchanger NHE-1 isoform in osteoblastic cells (UMR-106) via a cAMP-dependent pathway. J Biol Chem 1995, 270: 23166-72.
25. Ahlstrom M, Lamberg-Allardt C. Rapid protein kinase A-mediated activation of cyclic AMP-phosphodiesterase by parathyroid hormone in UMR-106 osteoblast-like cells. J Bone Miner Res 1997, 12: 172-8.
26. Johnson RS, Spiegelman BM, Papaioannou V. Pleiotropic effects of a null mutation in the c-fos proto-oncogene. Cell 1992, 71: 577-86.
27. Lee K, Deeds JD, Chiba S, Un-No M, Bond AT, Segre GV. Pa-rathyroid hormone induces sequential c-fos expression in bone cells in vivo: in situ localization of its receptor and c-fos messenger ribonucleic acids. Endocrinology 1994, 134: 441-50.
28. Bryant HU, Glasebrook AL, Yang NN, Sato M. Estrogen receptor basis for raloxifene action in bone. J Steroid Biochem Mol Biol 1999, 69: 37-44.
29. Balfour JA, Goa KL. Raloxifene. Drugs Aging 1998, 12: 335-41.
30. Rao LG, Liu LJ-F, Murray TM. Raloxifene stimulates mineralized bone nodule formation when added intermittently to cultures of SaOS-2 cells and ostgeogenic stem cells from normal human bone marrow preparations (hBMOSC). J Bone Min Res 2001 16 (suppl 1): S492.